Funding period: 2019-2024
Lead: Jessie Lavoie
Total GRDI funding: $1,190,000
Stem cell therapies are emerging as new treatments for patients with diseases that have currently limited therapeutic options. Extracellular vesicles derived from stem cells or exosomes are novel effectors related to the therapeutic effects of stem cells. Thus, extracellular vesicles are now regarded as new promising therapeutic drug delivery systems for a variety of applications including cancer immunotherapy. This project utilizes multiple 'omic' approaches and systems biology to identify indicators of high quality, safe and effective extracellular vesicles derived from stem cells. The latter are crucial for regulation where the knowledge and comprehension of these parameters are limited. The goal is to enhance the Health Canada's ability to evaluate the quality and safety of these innovative biologics and to provide clinically-compatible manufacturing processes, ultimately providing Canadians with access to high quality medicines.
Publications
- Gobin J, Muradia G, Mehic J, Westwood C, Couvrette L, Stalker A, Bigelow S, Luebbert CC, St-Denis Bissonnette F, Johnston MJW, Sauvé S, Tam RY, Wang L, Rosu-Myles M, Lavoie JR. 2021. Hollow-fiber bioreactor production of extracellular vesicles from human bone marrow mesenchymal stromal cells yields nanovesicles that mirrors the immuno-modulatory antigenic signature of the producer cell. Stem Cell Res. Ther. 12:e127. https://doi.org/10.1186/s13287-021-02190-3
- Munshi A, Mehic J, Creskey M, Gobin J, Gao J, Rigg E, Muradia G, Luebbert CC, Westwood C, Stalker A, Allan DS, Johnston MJW, Cyr T, Rosu-Myles M, Lavoie JR. 2019. A comprehensive proteomics profiling identifies NRP1 as a novel identity marker of human bone marrow mesenchymal stromal cell-derived small extracellular vesicles. Stem Cell Res. Ther. 10(1):e401. https://doi.org/10.1186/s13287-019-1516-2
- St-Denis-Bissonnette F, Khoury R, Mediratta K, El-Sahli S, WangL, Lavoie JR. 2022. Applications of Extracellular Vesicles in Triple-Negative Breast Cancer. Cancers (Basel). 14(2):451. https://doi.org/10.3390/cancers14020451
Contact us
For additional information, please contact:
Genomics R&D Initiative
Email: info@grdi-irdg.collaboration.gc.ca